Adding the measurement that post #150 says would settle it.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
I am describing what is, rather than arguing for what should be.